《Commercial Times》AmCad and Swiss Hospital Reveal Promising New Tech for OSA Treatment Success
AmCad BioMed (ticker: 4188) continues to expand the clinical application of its product, AmCAD-UO, in collaboration with the University Hospital of Bern, Switzerland, focusing on obstructive sleep apnea (OSA) screening and treatment. The research results were published earlier this month in the official peer-reviewed journal of the American Academy of Otolaryngology–Head and Neck Surgery, confirming AmCAD-UO’s role in improving the compatibility assessment for hypoglossal nerve stimulation (HNS) therapy.
Li Yili, general manager of AmCad BioMed, stated that hypoglossal nerve stimulation is an FDA-approved treatment for OSA. Approximately 2,000 patients in the US and a growing number in Europe receive this implant annually. Despite pre-treatment screening via drug-induced sleep endoscopy (DISE), about 40% of patients experience limited therapeutic outcomes. By analyzing tongue tissue characteristics, AmCAD-UO offers a non-invasive, rapid, and safe alternative to assess HNS outcomes with nearly 80% accuracy.
Source: https://www.ctee.com.tw/news/20250513700652-430504
are the trademarks owned by AmCad in Taiwan and/or in other countries. Unauthorized use of the AmCAD trademarks is prohibited unless specifically authorized.